CS130692A3 - Medicament for dementia treatment - Google Patents

Medicament for dementia treatment

Info

Publication number
CS130692A3
CS130692A3 CS921306A CS130692A CS130692A3 CS 130692 A3 CS130692 A3 CS 130692A3 CS 921306 A CS921306 A CS 921306A CS 130692 A CS130692 A CS 130692A CS 130692 A3 CS130692 A3 CS 130692A3
Authority
CS
Czechoslovakia
Prior art keywords
dementia
disturbances
present
improving
medicament
Prior art date
Application number
CS921306A
Other languages
English (en)
Inventor
Eiichi Otomo
Yoshiyuki Takasu
Tadashi Shiotani
Kazuo Hasegawa
Akira Honma
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of CS130692A3 publication Critical patent/CS130692A3/cs
Publication of CZ281170B6 publication Critical patent/CZ281170B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CS921306A 1991-05-02 1992-04-29 Léčivo pro léčení demence CZ281170B6 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22981991 1991-05-02
JP22981891 1991-05-02

Publications (2)

Publication Number Publication Date
CS130692A3 true CS130692A3 (en) 1992-11-18
CZ281170B6 CZ281170B6 (cs) 1996-07-17

Family

ID=26529012

Country Status (21)

Country Link
US (1) US5886023A (cs)
EP (1) EP0515866B1 (cs)
KR (1) KR100310590B1 (cs)
AT (1) ATE203402T1 (cs)
AU (2) AU1595492A (cs)
CA (1) CA2067614C (cs)
CZ (1) CZ281170B6 (cs)
DE (1) DE69231955T2 (cs)
DK (1) DK0515866T3 (cs)
ES (1) ES2160097T3 (cs)
GR (1) GR3036970T3 (cs)
HU (1) HU224689B1 (cs)
IE (1) IE921377A1 (cs)
IL (1) IL101738A (cs)
MX (1) MX9202058A (cs)
NO (1) NO312813B1 (cs)
PT (1) PT515866E (cs)
RU (1) RU2070042C1 (cs)
SG (1) SG49650A1 (cs)
SK (1) SK279285B6 (cs)
TW (1) TW199096B (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953356A4 (en) * 1996-10-01 2002-04-17 Daiichi Seiyaku Co MITOCHONDRIAL MEMBRANE STABILIZER
AU8131198A (en) 1997-07-15 1999-02-10 Daiichi Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for amnesia
IT1312107B1 (it) * 1999-05-14 2002-04-04 Umberto Cornelli Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile
KR20020015321A (ko) * 1999-05-31 2002-02-27 스즈키 다다시 신경 세포사 억제제
US20040077709A1 (en) * 1999-05-31 2004-04-22 Daiichi Pharmaceutical Co., Ltd. Neuronal death inhibitors
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6423739B1 (en) * 2000-02-23 2002-07-23 Daiichi Pharmaceutical Co., Ltd. Method for aiding cerebral recovery following neurodegeneration
US6348489B1 (en) * 2000-04-11 2002-02-19 Daiichi Pharmaceutical Co., Ltd. Method of treating traumatic brain injury and other neuronal disorders
CN1484527A (zh) * 2000-12-28 2004-03-24 ��һ��������ҩ��ʽ���� 神经性疼痛治疗和预防药
US20040192759A1 (en) * 2001-08-22 2004-09-30 Eiichi Otomo Use of nefiracetam for treating neurodegeneration
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
US7972633B2 (en) * 2007-02-07 2011-07-05 Applied Cognitive Sciences, LLC Nutritional supplements for healthy memory and mental function
RU2327480C1 (ru) * 2007-05-23 2008-06-27 Виктор Иванович Рощин Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения больных с дементным синдромом
EP3260118B1 (en) 2008-10-16 2021-03-24 The Johns Hopkins University Methods and compositions for improving cognitive function
US20110212928A1 (en) * 2010-02-09 2011-09-01 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE864269A (fr) * 1977-03-03 1978-06-16 Parke Davis & Co Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
IT1141287B (it) * 1979-06-13 1986-10-01 Nattermann A & Cie Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono
US4385053A (en) * 1981-03-11 1983-05-24 Barry Reisberg Treatment for human memory impairment associated with aging
JPH0699307B2 (ja) * 1987-08-20 1994-12-07 キッセイ薬品工業株式会社 抗痴呆剤
IT1231477B (it) * 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti

Also Published As

Publication number Publication date
HUT62790A (en) 1993-06-28
TW199096B (cs) 1993-02-01
DK0515866T3 (da) 2001-09-24
RU2070042C1 (ru) 1996-12-10
NO312813B1 (no) 2002-07-08
GR3036970T3 (en) 2002-01-31
HU224689B1 (hu) 2005-12-28
DE69231955D1 (de) 2001-08-30
MX9202058A (es) 1993-03-01
NO921724D0 (no) 1992-04-30
EP0515866B1 (en) 2001-07-25
EP0515866A1 (en) 1992-12-02
AU697936B2 (en) 1998-10-22
NO921724L (no) 1992-11-03
CA2067614C (en) 2002-07-30
US5886023A (en) 1999-03-23
SK279285B6 (sk) 1998-09-09
HU9201477D0 (en) 1992-07-28
SG49650A1 (en) 1998-06-15
DE69231955T2 (de) 2002-04-04
KR100310590B1 (ko) 2001-12-28
IE921377A1 (en) 1992-11-04
ES2160097T3 (es) 2001-11-01
IL101738A0 (en) 1992-12-30
CA2067614A1 (en) 1992-11-03
KR920021143A (ko) 1992-12-18
HK1002153A1 (en) 1998-07-31
AU3774595A (en) 1996-03-07
ATE203402T1 (de) 2001-08-15
AU1595492A (en) 1992-11-05
PT515866E (pt) 2001-11-30
CZ281170B6 (cs) 1996-07-17
IL101738A (en) 1999-01-26

Similar Documents

Publication Publication Date Title
GR3036970T3 (en) Use of N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl) acetamide for the treatment of dementia.
PT1040830E (pt) Medicamento para doencas neurodegenerativas
DE59109222D1 (de) Verwendung des Wirkstoffs Flupirtin zur Herstellung eines Arzneimittels zur Bekämpfung von Muskelverspannungen
DE4497905T1 (de) Pharmazeutische Zusammensetzung zur Prävention und Behandlung des Motion-Sickness-Syndroms
CA2106172A1 (en) Use of 2-(3,4-Dimethoxycinnamoyl)Aminobenzoic Acid for the Treatment of Restenosis Associated with Coronary Intervention
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
ATE252389T1 (de) Ein arzneimittel zur behandlung von fettleibigkeit und verbesserung des lipidmetabolismus
ATE78696T1 (de) Arzneimittelzubereitung zur behandlung des immunmangels.
IL91047A (en) Zinc complexes for the treatment of free radical- induced diseases
IL89031A0 (en) Medicaments containing a benzamide for the treatment or prevention of cognitive disorders and their preparation
HUT46046A (en) Process for producing compounds with nootropic effect and pharmaceutics comprising these as active ingredient
NO302472B1 (no) Sulfonylureaforbindelse, farmasöytisk formulering og anvendelse derav
DE69024060D1 (de) Osteogenesis-stimulierende mittel.
NO179472C (no) Opplösning omfattende benzoxoniumklorid for behandling av kontaktlinser, og anvendelse derav til konservering av kontaktlinser og legemidler for öynene
GR3034161T3 (en) Pharmaceutical composition for preventing or treating.
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
DK0826373T3 (da) Forebyggende middel mod postoperativ astigmatisme
ES2099736T3 (es) Utilizacion de derivados de la 15-deshidroxi-16-oxoprostaglandina en el tratamiento de las alergias.
ATE89288T1 (de) L-pyroglutamyl-l-cystein-dipeptid mit hoher anti- cataractogener wirkung und dies enthaltende pharmazeutische zusammensetzungen.
CA2154485A1 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders
UA30143C2 (uk) Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань
IL93728A0 (en) Antiviral pharmaceutical compositions containing cyclic amines
ATE316373T1 (de) Conagenin zur behandlung von ulzerativer kolitis und/oder morbus crohn

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20080429